Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Co-Diagnostics reports Q1 results, focuses on growth and innovation

Co-Diagnostics reported mixed financial results for Q1 2024, with revenue decrease but gross profit increase.
The company is strategically focused on commercialization efforts, product development, and managing expenses for growth.
Despite facing challenges such as net losses and operational complexities, Co-Diagnostics remains optimistic about future opportunities.
With a strong cash position and ongoing FDA submissions, Co-Diagnostics is poised for potential revenue growth and market expansion.

Co-Diagnostics reports Q3 revenue decline, focuses on global expansion

Co-Diagnostics faces financial challenges with a significant net loss in Q3 2024 but maintains a strong focus on advancing its testing platforms and expanding manufacturing capabilities.
Strategic opportunities in international market expansion and test development supported by grants present avenues for growth and market penetration.
Efforts to manage cash position through efficient spending and operational efficiencies underscore the company's commitment to future commercial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SALT LAKE CITY, May 4, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first-quarter 2021 results on Thursday, May 13, 2021, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Co-Diagnostics, Inc. Announces First-Quarter 2021 Earnings Release Date and Webcast

SALT LAKE CITY, April 29, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it will be accompanying Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Lab ("CRL") in a webinar titled "A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19" on Thursday, April 29 at 2:00 PM EDT. The 360Dx webinar is expected to provide insights regarding future applications of PCR testing for COVID-19, how CRL is able to provide non-invasive and highly accurate saliva PCR tests for at-home collection, and how new PCR science and technology is enabling and expanding the applications and accessibility of PCR tests.

Co-Diagnostics, Inc. and Partner CRL to Discuss Saliva Testing and Future Applications of PCR in 360Dx Webinar

Co-Diagnostics Inc (NASDAQ:CODX) has noted that its Indian manufacturing facility, CoSara Diagnostics Pvt Ltd, has garnered media attention for its actions to provide much-needed coronavirus (COVID-19) diagnostics as a wave of infections has led to the world's worst outbreak since the pandemic began. An article in the Times of India, as well as other media sources, have discussed the increased capacity that has resulted from CoSara's efforts to provide test kits and technical support for its government and private lab customers, Co-Diagnostics said.

Co-Diagnostics says its CoSara joint venture in India garnering media attention as it combats coronavirus surge

SALT LAKE CITY, April 28, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Indian manufacturing facility, CoSara Diagnostics Pvt. Ltd. ("CoSara," or the "JV", a Joint Venture with Synbiotics Ltd) has been featured in recent press highlighting its actions to provide much-needed COVID-19 diagnostics as a wave of infections has led to the world's worst COVID-19 outbreak since the pandemic began.

Co-Diagnostics, Inc. JV CoSara Diagnostics Recognized for Work Combating COVID-19 Surge in India

BioDelivery Sciences

Kamada

Surface Oncology Inc

Viemed Healthcare

As of April 21, the GuruFocus All-in-One Screener, a Premium feature, found that the following guru-owned utilities have low price-earnings ratios. While some of them are great value investments, others may need to be researched more carefully, according to the discounted cash flow calculator.

5 Health Care Stocks Trading with Low Price-Earnings Ratios

Co-Diagnostics Inc (NASDAQ:CODX), a molecular diagnostics company with a patented platform for the development of diagnostic tests, has revealed that its Logix Smart COVID-19 Test Kit was used by Australian researchers to demonstrate rapidly deployable mobile molecular diagnostics support for remote locations, with the peer-reviewed results published in the ‘Journal of Medical Microbiology.' The Utah-based company said the study was performed using readily available open-source equipment and materials that could be successfully operated in regional clinical laboratories, many of which are not currently equipped for molecular diagnostics.

Co-Diagnostics says Logix Smart COVID-19 Test performance validated by Australian researchers in peer-reviewed publication

SALT LAKE CITY, April 20, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ COVID-19 Test Kit was used by Australian researchers to demonstrate rapidly deployable mobile molecular diagnostics support for remote locations, with the peer-reviewed results published in the Journal of Medical Microbiology. The test demonstrated an analytical sensitivity of 1010 viral copies/ml, comparable to others used across W.

Co-Diagnostics, Inc. Test Performance Demonstrated by Australian Researchers in Peer-Reviewed Publication

CODX stock rose on the pandemic, but its prospects moving forward look bleak with a sales strategy that is suspect at best. The post If You Rode the Co-Diagnostics Stock Pandemic Highs, It's Time to Bail appeared first on InvestorPlace.

If You Rode the Co-Diagnostics Stock Pandemic Highs, It's Time to Bail

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan told Yahoo! Finance that “we believe COVID-19 will be here till the end of time” -- and that means individuals and organizations will need quick and easy tests partnered with vaccines to return to normalcy.

Co-Diagnostics CEO Egan says individuals and organizations will need DIY coronavirus tests partnered with vaccines to return to normalcy

Co-Diagnostics CEO Eagan says individuals and organizations will need DIY coronavirus tests partnered with vaccines to return to normalcy

SALT LAKE CITY, March 31, 2021 /PRNewswire/ -- The CEO of Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, appeared yesterday on Yahoo! Finance to comment on the Company's recently-released FY2020 earnings report, and to discuss its going-forward strategy as the world struggles to achieve normalization.

Co-Diagnostics, Inc. CEO Discusses Company Strategy for the Future with Yahoo! Finance

Analysts following this coronavirus stock have darkened their post-pandemic outlook.

Co-Diagnostics: Buy the Dip?

The company's recent struggles on the stock market continue.

Why Co-Diagnostics Stock Is Dropping Today

DocuSign

Cree

CytomX Therapeutics

DHT Holdings

Dow Inc

Medallia Inc

Nomura Holdings

With the trading day about halfway over, the broad markets were pushing lower. The Dow Jones industrial average and S&P 500 were only down slightly to start the week, while the Nasdaq faced the worst of it with about 1% pullback.

Co-Diagnostics, DocuSign, Dow, Nomura, Sea and More Monday Afternoon Analyst Calls

Develops products to detect infectious diseases in humans and animals Offers Logix Smart Coronavirus Disease detection test in US and globally Earned net income of $42.5 million in 2020 What Co-Diagnostics does:  Co-Diagnostics Inc (NASDAQ:CODX) is a molecular diagnostics company that develops products to detect infectious diseases in humans and animals. The company also develops tools for liquid-biopsy cancer screening and agricultural uses.

Co-Diagnostics joins fight against coronavirus (COVID-19) with flagship test

Investors didn't like what they heard in the company's fourth-quarter update.

Why Co-Diagnostics Stock Is Tanking Today

The company missed earnings expectations and hinted at slowing growth in 2021.

What Investors Didn't Like About Co-Diagnostics' Q4 Update

Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q4 2020 Results - Earnings Call Transcript

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of -12.24% and 1.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

CoDiagnostics, Inc. (CODX) Q4 Earnings Lag Estimates

Co-Diagnostics Inc (NASDAQ:CODX) announced Thursday that it earned a net income of $42.5 million in 2020 as its Logix Smart coronavirus (COVID-19) test drove record sales.  That's a huge turnaround for the Utah-based molecular diagnostics company which posted a $5.6 million loss in 2019.

Co-Diagnostics posts 2020 net income of $42.5M as its Logix Smart COVID-19 test drove record sales

Shares of Co-Diagnostics (NASDAQ:CODX) moved lower in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 577.78% year over year to $0.43, which missed the estimate of $0.48.

Recap: Co-Diagnostics Q4 Earnings

SALT LAKE CITY, March 25, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the fourth quarter and full year ended December 31, 2020. Fourth Quarter 2020 Financial Results: Revenue of $27.1 million, primarily due to sales of the Logix Smart™ COVID-19 Test Gross profit increased to $22.8 million, representing 84.1% of consolidated revenue due to improved product mix as compared to the prior-year period Operating income improved to $16.0 million, due to record revenue and gross profit Income before taxes of $15.8 million Net income of $12.8 million, compared to a net loss of $1.7 million in the prior-year fourth quarter, representing $0.43 per fully diluted share Full Year 2020 Financial Results: Revenue of $74.6 million, an increase of $74.3 million, primarily due to sales of Logix Smart COVID-19 Tests throughout the world Gross profit increased to $58.0 million, representing 77.7% of consolidated revenue Operating income improved to $41.7 million due to record revenue and gross profit for the year Income before taxes of $42.6 million Net income of $42.5 million, compared to a loss of $5.6 million from the prior year, representing $1.52 per fully diluted share, and reflecting a full utilization of historical net operating losses Cash, cash equivalents, and marketable securities totaled $47.3 million as of December 31, 2020, an increase of $46.4 million from December 31, 2019 "This year marked a critical inflection point in our ability to establish Co-Diagnostics as a leading global molecular diagnostic company, driving innovation through our proprietary technologies across the infectious disease market," said Dwight Egan, Co-Diagnostics' Chief Executive Officer.

Co-Diagnostics Reports Fourth-Quarter and Full-Year 2020 Financial Results

CODX stock's true value isn't fully appreciated by the investing community, and this could provide a setup for an explosive move. The post Co-Diagnostics Stock Is an Out-and-Out Buy Before the Earnings Release appeared first on InvestorPlace.

Co-Diagnostics Stock Is an Out-and-Out Buy Before the Earnings Release

SALT LAKE CITY, March 18, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth-quarter and full-year 2020 results on March 25, 2021, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Co-Diagnostics, Inc. Announces Fourth-Quarter and Full-Year 2020 Earnings Release Date and Webcast

SALT LAKE CITY, March 16, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has been invited to present at the Maxim Group LLC and M Vest LLC Inaugural Emerging Growth Virtual Conference, held virtually March 17-18, 2021. The Company's presentation is expected to include a discussion of its at-home and point-of-care rapid PCR diagnostics platform currently in development, as the platform relates to supporting COVID-19 testing initiatives at the places where interactions take place to help normalize work, school, home and travel routines.

News for Co-Diagnostics Stock (CODX)